glp-1 medication competitors pharmaceutical companies Agonists Market Report 2025-2033, By Product, Molecule, and Geo GLP-1 Drugs Market Size to

Establishing microbial composition measurement standards with reference frames

Liraglutide | Drugs BNF NICE

It combines BPC157 and TB500 to try to speed up healing from injuries and surgery

Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events